Mesenchymal stem cell-based NK4 gene therapy in nude mice bearing gastric cancer xenografts

  title={Mesenchymal stem cell-based NK4 gene therapy in nude mice bearing gastric cancer xenografts},
  author={Yin Zhu and Ming Cheng and Zhen Yang and Chunyan Zeng and Jiang Chen and Yong Xie and Shi-wen Luo and Kun-He Zhang and Shufeng Zhou and Nonghua Lu},
  journal={Drug Design, Development and Therapy},
  pages={2449 - 2462}
  • Yin Zhu, M. Cheng, N. Lu
  • Published 9 December 2014
  • Biology, Medicine
  • Drug Design, Development and Therapy
Mesenchymal stem cells (MSCs) have been recognized as promising delivery vehicles for gene therapy of tumors. Gastric cancer is the third leading cause of worldwide cancer mortality, and novel treatment modalities are urgently needed. NK4 is an antagonist of hepatocyte growth factor receptors (Met) which are often aberrantly activated in gastric cancer and thus represent a useful candidate for targeted therapies. This study investigated MSC-delivered NK4 gene therapy in nude mice bearing… 

Figures from this paper

Effects of human placenta‐derived mesenchymal stem cells with NK4 gene expression on glioblastoma multiforme cell lines

Examination of the antitumor effects of manipulating human placenta‐derived mesenchymal stem cells with NK4 expression with PDMSC‐NK4 on GBM cells suggested that PDMSCs can also be applied as an ideal cellular vehicle to target the glioblastoma multiforme.

Application of Mesenchymal Stem Cells for Therapeutic Agent Delivery in Anti-tumor Treatment

Mesenchymal stem cells are non-hematopoietic progenitor cells, which can be isolated from different types of tissues including bone marrow, adipose tissue, tooth pulp, and placenta/umbilical cord blood, and are considered as a new therapeutic agent and drug delivery vector.

Umbilical cord‐derived mesenchymal stromal/stem cells expressing IL‐24 induce apoptosis in gliomas

Findings indicate that UC‐MSC‐based IL‐24 gene therapy may be able to suppress the growth of glioma xenografts, thereby suggesting possible future therapeutic use in the treatment ofgliomas.

Mesenchymal stem cells as professional actors in gastrointestinal cancer therapy: From Naïve to genetically modified

The characteristics and utility of Mesenchymal stem cells in cancer therapy are overviewed, the application of naïve MSCs and utilization of M SCs in the delivery of therapeutic agents in GI cancer therapy is discussed, and more information about harnessing of genetically modified MSCS inGI cancer treatment will be presented.

Harnessing mesenchymal stem cell homing as an anticancer therapy

This review will focus on the current developments of MSC-based gene therapy, in particular the diverse approaches that have been used for MSCs-targeted tumor therapy and some outstanding issues.

Mesenchymal Stem Cells as Vectors for Cancer Therapy

In this chapter, updated information on the applications of engineered MSCs for cancer therapy will be discussed.

Mesenchymal Stem Cells in Gastric Cancer: Vicious but Hopeful

Current advances concerning the reciprocal metabolic interactions between MSC and GC and their underlying therapeutic implications in the future are summarized.

Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review

This systematic review represents the first thorough evaluation of the impact of experimental anti-cancer therapies based on MSC of human origin and discusses how this information can serve as a guide map for optimal experimental design implementation ultimately aiding the effective transition into clinical trials.

Tracking GFP-labeled Transplanted Mouse MSC in Nude Mice Using in Vivo Fluorescence Imaging

The purpose of this study was to monitor the fate of GFP-labeled transgenic Mouse MSC in Nude Mice using in Vivo Fluorescence Imaging.



Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells

MSC-based gene therapy did not induce the severe adverse effects induced by conventional adenoviral vectors, indicating that MSCs can serve as a vehicle of gene therapy for targeting multiple lung metastatic tumors.

Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model

This is the first study that demonstrates the potential therapeutic utility of Ad.TR‐transduced MSCs in cancer cells and the stability of this vector in the context of the blood environment.

Stem and progenitor cell-mediated tumor selective gene therapy

It is demonstrated that neural and mesenchymal stem cells can deliver therapeutic genes to elicit a significant antitumor response in animal models of intracranial glioma, medulloblastoma, melanoma brain metastasis, disseminated neuroblastoma and breast cancer lung metastasis.

Cancer gene therapy using mesenchymal stem cells

The potential of MSCs as cellular vehicles for targeted cancer therapy and the molecular mechanisms underlying MSC accumulation at tumor sites are reviewed.

Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival

Peritumoral injection of Ad-NK4 plus GEM is a potent combination therapy for pancreatic cancer, and Histologic and immunohistochemical assays of primary tumors indicated that combination therapy prohibited both cell proliferation and angiogenesis, resulting in high levels of apoptosis.

VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma

It is shown that mesenchymal stem cells supported tumour angiogenesis in vivo, that is CD31+ vessel density was increased after the transfer of MSC compared with siVEGF-MSC, and a supportive role inAngiogenesis is suggested.

Suppression of human colon tumor growth by adenoviral vector-mediated NK4 expression in an athymic mouse model.

AIM To investigate the suppressive effects of adenoviral vector-mediated expression of NK4, an antagonist of hepatocyte growth factor (HGF), on human colon cancer in an athymic mouse model to explore

TGF-β mediates homing of bone marrow-derived human mesenchymal stem cells to glioma stem cells.

The TGF-β/TGFβR axis is revealed as a mediator of the tropism of BM-hMSCs for GSCs and it is suggested that T GF-β predicts patients in whom BM- hMSC delivery will be effective.